Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (10)
Yoshihisa Ishiura, Masaki Fujimura, Noriyuki Ohkura, Johsuke Hara, Kazuo Kasahara, Nobuyasu Ishii, Yusuke Sawai, Toshiki Shimizu, Takeshi Tamaki & Shosaku Nomura. (2020) Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap. International Journal of Chronic Obstructive Pulmonary Disease 15, pages 269-277.
Read now
Read now
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D’Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Don D. Sin & Darcy D. Marciniuk. (2019) Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 3:4, pages 210-232.
Read now
Read now
Anthony D D’Urzo, Peter Kardos & Russell Wiseman. (2018) Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1089-1104.
Read now
Read now
Jean Bourbeau, Mohit Bhutani, Paul Hernandez, Darcy D. Marciniuk, Shawn D. Aaron, Meyer Balter, Marie-France Beauchesne, Anthony D'Urzo, Roger Goldstein, Alan Kaplan, François Maltais, Denis E. O'Donnell & Don D. Sin. (2017) CTS position statement: Pharmacotherapy in patients with COPD—An update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine 1:4, pages 222-241.
Read now
Read now
Oskar Eklund, Faraz Afzal, Fredrik Borgström, Jason Flavin, Andrew Ternouth, Maria Eugenia Ojanguren, Carlos Crespo & Mike Baldwin. (2016) Cost-effectiveness of tiotropium versus glycopyrronium in moderate to very severe chronic obstructive pulmonary disease in Canada, Spain, Sweden, and the UK. ClinicoEconomics and Outcomes Research 8, pages 243-252.
Read now
Read now
Craig LaForce, Gregory Feldman, Selwyn Spangenthal, Joerg H Eckert, Michelle Henley, Francesco Patalano & Peter D’Andrea. (2016) Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study. International Journal of Chronic Obstructive Pulmonary Disease 11, pages 1233-1243.
Read now
Read now
Charlotte Suppli Ulrik. (2015) Once-daily glycopyrronium bromide (Seebri Breezhaler®) for the treatment of chronic obstructive pulmonary disease (COPD). Expert Opinion on Pharmacotherapy 16:17, pages 2653-2659.
Read now
Read now
Anthony D D’Urzo, Edward M Kerwin, Kenneth R Chapman, Marc Decramer, Robert DiGiovanni, Peter D’Andrea, Huilin Hu, Pankaj Goyal & Pablo Altman. (2015) Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 1599-1612.
Read now
Read now
Chen Wang, Tieying Sun, Yijiang Huang, Michael Humphries, Lingyan Bai, Lilly Li, Qian Wang, Pearl Kho, Roz Firth & Peter D’Andrea. (2015) Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 57-68.
Read now
Read now
Anoop Prakash, K Suresh Babu & Jaymin B Morjaria. (2015) Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD. International Journal of Chronic Obstructive Pulmonary Disease 10, pages 111-123.
Read now
Read now
Articles from other publishers (17)
José Luis Lopez-Campos, Rocio Reinoso-Arija, Marta Ferrer Galván, Auxiliadora Romero Falcón, Francisco J. Alvarez-Gutiérrez, Francisco Ortega-Ruiz & Esther Quintana-Gallego. (2023) Evaluation of Different Doses in Inhaled Therapy: A Comprehensive Analysis. Pharmaceutics 15:9, pages 2206.
Crossref
Crossref
Luigino Calzetta, Beatrice Ludovica Ritondo, Maria Cristina Zappa, Gian Marco Manzetti, Andrea Perduno, Janis Shute & Paola Rogliani. (2022) The impact of long-acting muscarinic antagonists on mucus hypersecretion and cough in chronic obstructive pulmonary disease: a systematic review. European Respiratory Review 31:164, pages 210196.
Crossref
Crossref
I. V. Demko, M. G. Mamaeva, E. A. Sobko, A. Yu. Kraposhina & N. V. Gordeeva. (2022) Experience with the triple fixed combination in patients with chronic obstructive pulmonary disease. Meditsinskiy sovet = Medical Council:21-1, pages 80-85.
Crossref
Crossref
Yasuhito Suzuki, Suguru Sato, Kento Sato, Sumito Inoue & Yoko Shibata. (2022) Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respiratory Investigation 60:1, pages 108-118.
Crossref
Crossref
Ioanna Tsiligianni & Janwillem W. H. Kocks. (2020) Daytime symptoms of chronic obstructive pulmonary disease: a systematic review. npj Primary Care Respiratory Medicine 30:1.
Crossref
Crossref
Chenglong Li, Yumin Zhou, Sha Liu, Mengning Zheng, Jinzhen Zheng, Huanhuan Peng, Zhishan Deng, Nanshan Zhong & Pixin Ran. (2019) Tiotropium discontinuation in patients with early-stage COPD: a prospective observational cohort study. ERJ Open Research 5:1, pages 00175-2018.
Crossref
Crossref
Yong-Bum Park, Chin Kook RheeHyoung Kyu YoonYeon-Mok OhSeong Yong LimJin Hwa LeeKwang-Ha Yoo & Joong Hyun Ahn. (2018) Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A Summary. Tuberculosis and Respiratory Diseases 81:4, pages 261.
Crossref
Crossref
Satyadeo Choubey & Babaji Ghewade. (2017) PHARMACOTHERAPY IN COPD- RECENT INNOVATIONS AND RESEARCH. Journal of Evidence Based Medicine and Healthcare 4:91, pages 5512-5517.
Crossref
Crossref
David M. Halpin, Alan G. Kaplan & Richard K. Russell. (2017) Why choose tiotropium for my patient? A comprehensive review of actions and outcomes versus other bronchodilators. Respiratory Medicine 128, pages 28-41.
Crossref
Crossref
Hyoung Kyu YoonYong-Bum ParkChin Kook RheeJin Hwa LeeYeon-Mok Oh. (2017) Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease. Tuberculosis and Respiratory Diseases 80:3, pages 230.
Crossref
Crossref
James F. Donohue, Weily Soong, Xiao Wu, Pomy Shrestha & Alejhandra Lei. (2016) Long-term safety of aclidinium bromide/formoterol fumarate fixed-dose combination: Results of a randomized 1-year trial in patients with COPD. Respiratory Medicine 116, pages 41-48.
Crossref
Crossref
Peter Calverley & Ben Vlies. (2016) A rational approach to single, dual and triple therapy in COPD. Respirology 21:4, pages 581-589.
Crossref
Crossref
Claudie Rodrigue, Marie-France Beauchesne, François Savaria, Amélie Forget, Catherine Lemière, Pierre Larivée & Lucie Blais. (2016) Adverse events among COPD patients treated with long-acting anticholinergics and β2-agonists in an outpatient respiratory clinic. Respiratory Medicine 113, pages 65-73.
Crossref
Crossref
Oskar Eklund, Faraz Afzal & Fredrik Borgström. (2015) Cost-effectiveness of tiotropium versus usual care and glycopyrronium in the treatment of chronic obstructive pulmonary disease in Sweden. Cost Effectiveness and Resource Allocation 13:1.
Crossref
Crossref
Paul W. Jones. (2015) Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease 9:3, pages 84-96.
Crossref
Crossref
T. Welte, C. Vogelmeier & A. Papi. (2015) COPD: early diagnosis and treatment to slow disease progression. International Journal of Clinical Practice 69:3, pages 336-349.
Crossref
Crossref
Marc Miravitlles, Kai-Michael Beeh & Pablo Altman. (2014) Glycopyrronium for chronic obstructive pulmonary disease: evidence and rationale for use from the GLOW trials. Clinical Investigation 4:12, pages 1095-1111.
Crossref
Crossref